DRX-065, deuterium-stabilized R-pioglitazone, is a clinical candidate that has been acquired by Poxel and is being pursued for nonalcoholic steatohepatitis (NASH).

  • Pioglitazone (pio) is the most extensively studied drug for NASH and has demonstrated “resolution of NASH without worsening of fibrosis” in a Phase 4 trial (Ann Intern Med. 2016, 165(5), 305-315). Pio is the only drug recommended for biopsy-proven NASH patients by the Practice Guidelines published by the by AASLD and EASL. Pio’s use for NASH, however, has been limited due to the PPARγ-related side effects, which include weight gain, bone fractures, and fluid retention.
  • In in vitro studies, DRX-065 has been shown to target mitochondrial pyruvate carrier (MPC). In preclinical models, DRX-065 exhibits the anti-inflammatory activity and NASH efficacy associated with pio with little or no weight gain or fluid retention, side effects which are associated with S-pio.
  • Based upon preclinical and Phase 1 results to date, DRX-065 is anticipated to show a better therapeutic profile than pio, including enhanced efficacy and a reduction of side effects, such as those associated with PPAR-γ activation.

DRX-164, deuterium-stabilized S-avadomide, is in preclinical development at DeuteRx for hematological malignancies and solid tumors.

  • Avadomide (CC-122) is in clinical development at Celgene as the first in a new series of cereblon E3 ligase modulators (CELMoDs®). It is more potent than lenalidomide and is being studied in clinical trials without dexamethasone.
  • In preclinical models, DRX-164 exhibits the cereblon binding, anti-inflammatory, and anti-tumorigenic activity of CC-122 while the R-stereoisomer exhibits potential tumor-promoting effects in a xenograft model of multiple myeloma.

  • For additional information, please contact:
    • DeuteRx, LLC
    • 300 Brickstone Square, Suite 201
    • Andover MA 01810
    • Phone: 978-662-5287
      Email: info@deuterx.com
Compelling Commercial Strategy
& Large Portfolio of
Product Opportunities